Drugs / Resiquimod
Trials 32
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT01748747 | Oct 2012 → Dec 2014 | melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT00470379 | Apr 2006 → Oct 2011 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05361005 | Mar → May 2020 | — | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05075304 | Feb → Apr 2020 | COVID-19 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT04196530 | Nov 2019 → Jul 2024 | — | Eikon Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05360927 | Sep 2019 → Dec 2020 | — | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03486301 | Feb 2018 → Mar 2024 | soft tissue neoplasm | Eikon Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00821652 | Feb 2009 → Jan 2010 | neoplasm | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05197842 | Feb 2022 → Mar 2025 | anti-neutrophil cytoplasmic antibody-associated vasculitis | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT05103423 | Jun 2021 → Jul 2023 | hidradenitis suppurativa | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT01808950 | Feb → Aug 2013 | nodular basal cell carcinoma | Spirig Pharma Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01676831 | Feb 2012 → Jan 2015 | primary cutaneous T-cell lymphoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00948961 | Sep 2009 → Jun 2012 | cancer | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT06246110 | Feb 2024 → Dec 2026 expected | non-small cell lung carcinoma | Eikon Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04819373 | Aug 2021 → Apr 2023 | — | Eikon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05093855 | Aug 2021 → Aug 2023 | hidradenitis suppurativa | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03915678 | Mar 2021 → Dec 2026 expected | malignant pancreatic neoplasm, melanoma, non-small cell lung carcinoma, triple-negative breast carcinoma +2 | Institut Bergonié | Recruiting | No outcome recorded |
| Phase 2 | NCT03292406 | Dec 2017 → Mar 2020 | primary cutaneous T-cell lymphoma | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT01583816 | May 2012 → Nov 2013 | actinic keratosis | Spirig Pharma Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01204684 | Oct 2010 → Aug 2024 | anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01094496 | Apr 2010 → Jul 2011 | urinary bladder cancer | Celldex Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00116662 | Mar 2005 → ? | common wart | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00116675 | Mar 2005 → Apr 2006 | common wart | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00117871 | Oct 2004 → ? | common wart | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00117923 | Aug 2004 → ? | common wart | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00115141 | Apr 2004 → ? | common wart | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00114920 | Mar 2004 → ? | common wart | Graceway Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07365319 | Jun 2026 → Dec 2035 expected | non-small cell lung carcinoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06697301 | May 2025 → Dec 2035 expected | melanoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04449588 | Jul 2020 → Mar 2024 | pneumonia | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07168161 | Nov 2025 → Apr 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06021002 | Aug 2022 → Sep 2024 | allergic rhinitis, asthma, autoinflammatory syndrome | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01737580 Comparator | Apr → Jun 2013 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00960752 Comparator | May 2010 → Jul 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT06488118 Comparator | May 2024 → May 2025 overdue | asthma, viral infectious disease | Akhilesh Jha | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-05-30 | Eikon Therapeutics | Results Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology eikontx.com ↗
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development |
| 2026-05-26 | Noxopharm Limited | Results New data confirms cancer-fighting potential noxopharm.com ↗
When combined with a systemically delivered TLR8-potentiating oligonucleotide, the immune response in the spleen increased three-fold compared to the agonist alone. |
| 2025-01-03 | Beijing Shenogen Biomedical Co., Ltd | Results 中国科技新闻网&药渡：复旦大学发现淫羊藿素联合免疫佐剂与经动脉放射栓塞术TARE用于肝癌治疗的新方法 shenogen.com ↗
在大鼠原位 N1S1 HCC 模型中，抗肿瘤效果显著增强且无复发。 |
| 2024-05-28 | Eikon Therapeutics | Results Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting eikontx.com ↗
The new data show that EIK1001 was well-tolerated with a manageable safety profile, and showed encouraging preliminary efficacy across several tumor types in combination with pembrolizumab. |
| 2024-04-12 | Eikon Therapeutics | Results Eikon Therapeutics Presents Pharmacokinetic/Biomarker Analysis of the Toll-Like Receptor 7 and 8 (TLR7/8) Agonist EIK1001 at the Annual Meeting of the American Association for Cancer Research eikontx.com ↗
Dose-dependent increases in IP-10 and IFNg are consistent with the TLR7/8 mechanism of action, over a dose range where clinical response was observed in the heavily treated and heterogenous Phase 1 population. |
All press releases naming this drug 8 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resiquimod | “The investigators have already developed a well-tolerated mimic of human viral infection using a sterile substance called Resiquimod (or R848).” NCT06488118 ↗17“In this study we will use a nasal spray containing a sterile substance called Resiquimod (also called R848) to mimic a viral infection.” NCT06021002 ↗ “CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)” NCT01094496 ↗ |
| Known as | BDB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05197842 ↗ |
| Known as | CD11301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03292406 ↗ |
| Known as | EIK1001 | “BDB001 (EIK1001) is an immunotherapy agent.” NCT03486301 ↗ |
| Known as | R848 | “The investigators have already developed a well-tolerated mimic of human viral infection using a sterile substance called Resiquimod (or R848).” NCT06488118 ↗ |
| Known as | S-28463 | ChEMBL registry synonym — accepted as the source's own label CHEMBL383322 ↗ |
| Action | Activate | “the Toll-like receptor (TLR) agonists resiquimod (TLR7/8)” PMID 24739759 ↗ Apr 20141“Toll-like receptor 8 agonist” CHEMBL383322 ↗ |
| Modality | Other / unclassified | “BDB001 is an immunotherapy agent.” NCT04819373 ↗ |
| Modality | Small molecule | — CHEMBL383322 ↗ |
| Route | Topical | “topical gel” NCT00114920 ↗ |
| Target | TLR7 | “BDB001 is a Toll-like receptor 7/8 (TLR7/8) agonist delivered intravenously” NCT04819373 ↗ |
| Target | TLR8 | “Toll-like receptor 8 agonist” CHEMBL383322 ↗ |